#1 Clinical Trials Search in Europe

Satoreotide Trizoxetan Gallium Ga-68

Satoreotide Trizoxetan Gallium Ga-68 is an innovative imaging agent being studied in clinical trials for its potential in diagnosing and monitoring certain types of cancer. This radioactive tracer is designed to be used with Positron Emission Tomography (PET) scans, offering a new way to visualize tumors in patients with neuroendocrine cancers, including lung cancer and neuroblastoma. The ongoing research aims to evaluate its safety, effectiveness, and potential advantages over current imaging techniques.

Table of Contents

What is SATOREOTIDE TRIZOXETAN GALLIUM GA-68?

SATOREOTIDE TRIZOXETAN GALLIUM GA-68 is a new diagnostic tool being studied for its potential in detecting certain types of cancer[1]. It is also known by other names such as OPS-202 GA-68 or 68Ga-SATO[2]. This substance is what’s called a “PET tracer,” which means it’s used in a special type of imaging scan called Positron Emission Tomography (PET)[1].

How Does It Work?

When injected into the body, SATOREOTIDE TRIZOXETAN GALLIUM GA-68 attaches to specific proteins found on the surface of certain cancer cells. The gallium-68 part of the molecule gives off a small amount of radiation that can be detected by a PET scanner. This allows doctors to see where these cancer cells are in the body[1].

Medical Conditions It Can Help Diagnose

Current research is focusing on using SATOREOTIDE TRIZOXETAN GALLIUM GA-68 to diagnose several types of cancer:

  • High-grade neuroendocrine lung cancer, including:
    • Large cell neuroendocrine lung cancer (LCNEC)
    • Small cell lung cancer (SCLC)[1]
  • Neuroblastoma in children[2]

These cancers can be difficult to detect and monitor with conventional imaging techniques, so a more accurate method could greatly improve patient care.

How Is It Administered?

SATOREOTIDE TRIZOXETAN GALLIUM GA-68 is given as a solution for injection. It’s typically injected into a vein (intravenously) before a PET/CT scan[1][2]. The dose is measured in units called megabecquerels (MBq), with a maximum dose of about 200 MBq for adults[1].

Potential Benefits

Researchers are studying SATOREOTIDE TRIZOXETAN GALLIUM GA-68 for several potential benefits:

  1. Improved detection of cancer lesions: It may be able to identify cancer sites that other imaging methods miss[1].
  2. Quantification of cancer activity: The PET scan can measure how much of the tracer is taken up by tumors, which might indicate how active the cancer is[1].
  3. Faster imaging: The procedure time for SATOREOTIDE TRIZOXETAN GALLIUM GA-68 PET/CT might be shorter than some other imaging methods[2].
  4. Comparison with current methods: Studies are comparing this new method with current standard imaging techniques to see if it provides better or additional information[2].

Safety and Side Effects

As with any medical procedure, safety is a top priority. Current studies are specifically designed to assess the short-term safety and tolerability of SATOREOTIDE TRIZOXETAN GALLIUM GA-68[2]. Side effects, if any occur, will be carefully monitored and recorded using a standardized system called CTCAE (Common Terminology Criteria for Adverse Events)[2].

It’s important to note that some patients may not be eligible to receive this tracer, including:

  • People with severe autoimmune diseases
  • Those who have recently used certain medications like long-acting somatostatin analogs or diuretics
  • Pregnant individuals[2]

Ongoing Research

SATOREOTIDE TRIZOXETAN GALLIUM GA-68 is still being studied and is not yet approved for general use. Current research aims to:

  • Determine how well it detects cancer compared to current imaging methods
  • Measure the radiation dose patients receive
  • Assess its safety and any potential side effects
  • Evaluate its effectiveness in different types of neuroendocrine cancers[1][2]

These studies will help determine if SATOREOTIDE TRIZOXETAN GALLIUM GA-68 could become a valuable tool in the diagnosis and monitoring of certain cancers in the future.

Aspect Details
Drug Name Satoreotide Trizoxetan Gallium Ga-68
Purpose Imaging agent for PET/CT scans
Cancer Types Studied High-grade neuroendocrine lung cancer (SCLC, LCNEC), Neuroblastoma in children
Main Objectives Evaluate uptake in tumors, compare with standard imaging, assess safety and tolerability
Key Measurements SUV values, tumor-to-background ratio, number and location of detected lesions
Potential Benefits Improved tumor detection, faster imaging procedure, potential for better treatment monitoring
Safety Considerations Short-term safety assessment, monitoring for adverse events

FAQ

  • What is Satoreotide Trizoxetan Gallium Ga-68? Satoreotide Trizoxetan Gallium Ga-68 is a radioactive imaging agent used in PET scans. It's being studied to help doctors see certain types of cancer more clearly, especially neuroendocrine tumors in the lungs and neuroblastoma in children.
  • How is this imaging agent used in clinical trials? In the trials, patients receive an injection of Satoreotide Trizoxetan Gallium Ga-68 before undergoing a PET/CT scan. The researchers then study how well the agent shows cancer cells compared to standard imaging methods like CT scans or other types of PET scans.
  • What types of cancer are being studied with this agent? The clinical trials are focusing on high-grade neuroendocrine lung cancers, including small cell lung cancer and large cell neuroendocrine lung cancer. It's also being studied in children with neuroblastoma, a type of cancer that often affects young children.
  • Are there any safety concerns with using this imaging agent? The trials are designed to assess the short-term safety and tolerability of Satoreotide Trizoxetan Gallium Ga-68. Like all medical procedures, there may be some risks, which is why the researchers are carefully monitoring patients for any side effects or adverse reactions.
  • How might this new imaging technique benefit patients? If successful, this new imaging technique could provide more accurate and detailed images of certain types of cancer. This could help doctors better diagnose the cancer, determine its extent, and monitor how well treatments are working. It may also be faster and more convenient than some current imaging methods.

Ongoing Clinical Trials on Satoreotide Trizoxetan Gallium Ga-68

  • Study of 68Ga Satoreotide Trizoxetan PET/CT in Patients with High-Grade Neuroendocrine Lung Cancer

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

Glossary

  • PET (Positron Emission Tomography): A type of imaging test that uses a small amount of radioactive material to show how organs and tissues are working. It's often combined with CT scans to provide detailed pictures of the body.
  • CT (Computed Tomography): An imaging method that uses X-rays to create detailed cross-sectional pictures of the body.
  • Neuroendocrine tumor: A type of tumor that begins in specialized cells called neuroendocrine cells. These cells have traits similar to nerve cells and hormone-producing cells.
  • Small cell lung cancer (SCLC): A fast-growing type of lung cancer that usually starts in the bronchi (center of the chest).
  • Large cell neuroendocrine lung cancer (LCNEC): A rare and aggressive type of lung cancer that is part of the neuroendocrine tumor family.
  • Neuroblastoma: A type of cancer that develops from immature nerve cells. It most commonly affects children, usually under the age of 5.
  • Standardized Uptake Value (SUV): A measurement used in PET imaging to show how much of the radioactive tracer is taken up by tissue. Higher values often indicate more active disease.
  • Tumor-to-background ratio: A comparison of how much of the imaging agent is taken up by the tumor versus normal tissue. A higher ratio can make tumors easier to see.
  • CTCAE: Common Terminology Criteria for Adverse Events, a set of criteria for the standardized classification of side effects of drugs used in cancer therapy.
  • Somatostatin analogs: Drugs that mimic the action of somatostatin, a natural hormone in the body. They are sometimes used to treat certain types of neuroendocrine tumors.

References

  1. http://clinicaltrials.eu/trial/study-of-68ga-satoreotide-trizoxetan-pet-ct-in-patients-with-high-grade-neuroendocrine-lung-cancer/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-of-68ga-sato-and-iodine-123i-iobenguane-in-children-with-neuroblastoma/